Product Description
Zhengda Tianqing Pharmaceutical Group/Sailing Pharmaceutical Technology/Zhengda Tianqing Pharmaceutical Group is developing tq-b3234, an Oral MEK1 Inhibitor,MEK2 Inhibitor for Advanced Cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02996838)
Mechanisms of Action: MEK1 Inhibitor,MEK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Neurofibroma|Neurofibromatoses|Neurofibromatosis 1
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TQ-B3234-I-02 | P1 |
Not yet recruiting |
Neurofibromatosis 1|Neurofibromatoses |
2023-12-01 |
40% |
CTR20212106 | P1 |
Recruiting |
Neurofibroma |
None |